Aurinia Pharm Ord (AUPH) Stock Price, Quote & News

Company Profile

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement wit...

Industry: Biotechnology

Sector: Healthcare

Phone: 250 744 2487

Fax: 250 708 4345

Website: www.auriniapharma.com

Address:

#140, 14315 – 118 Avenue, Edmonton, Canada

US_Bull Oct. 27 at 7:14 PM

$AUPH Patent approval will take this straight through 14$+ in a blink of an eye we are close.

4 · Reply

US_Bull Oct. 27 at 7:12 PM

$AUPH I loaded more today another 1,300 shares.

0 · Reply

GeorgeTitmunchFDA Oct. 27 at 7:08 PM

$AUPH The Bull needs to keep charging Right over Skidmark's Ass

0 · Reply

RicardoDelJuego Oct. 27 at 7:07 PM

$AUPH From the linked poster - further consolidation of Lupkynis's safety efficacy and safety profiles, as well as rebuttal of Tidmarsh's claims.

1 · Reply

Yarrow Oct. 27 at 7:07 PM

$AUPH $15 stock after earnings.

0 · Reply

jdoldnumber7 Oct. 27 at 7:01 PM

$AUPH 1.28M shares traded with 1 hour remaining. Up .40 cents.

1 · Reply

Yarrow Oct. 27 at 6:53 PM

$AUPH Aurinia Pharmaceuticals Advances Lupus Nephritis Study in Young Patients - TipRanks.com https://share.google/QYbrYAjD6LDESSN0P

0 · Reply

BudFox121187 Oct. 27 at 4:40 PM

$AUPH Loading, All Aboard!

0 · Reply

jdoldnumber7 Oct. 27 at 4:32 PM

$AUPH Passing 900K...

0 · Reply

BABYHAIR Oct. 27 at 4:29 PM

$AUPH One more breadcrumb to spark discussion, anyone remember Gilead "sniffing" around Aurinia in late 2023? Interesting to note they have a deal with Galapagos. https://pharmaphorum.com/news/galapagos-drops-plan-split-after-market-developments The proposal also saw a 10-year, $5.1 billion R&D alliance with Gilead Sciences significantly amended, with Galapagos regaining full rights to the pipeline of partnered projects. The company said it would stop working on small-molecule drugs, including TYK2 inhibitor GLPG3667, which is in phase 2 trials for systemic lupus erythematosus (SLE) and dermatomyositis, and seek development partners for these programmes.

1 · Reply

Aurinia Pharmaceuticals: Lupkynis Growth And AUR200 Pipeline Justify Buy Rating

Oct 15, 2025, 6:00 AM EDT - 12 days ago

Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025

Sep 29, 2025, 8:27 PM EDT - 27 days ago

Aurinia Responds to Now Retracted LinkedIn Post

Aug 6, 2025, 6:02 PM EDT - 2 months ago

Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)

Jul 31, 2025, 5:57 PM EDT - 3 months ago

Aurinia Pharmaceuticals Inc. (AUPH) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 6:00 AM EDT - 3 months ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025

Jul 22, 2025, 6:00 AM EDT - 3 months ago

Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025

Jul 7, 2025, 12:49 PM EDT - 4 months ago

The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity

Jun 30, 2025, 6:00 AM EDT - 4 months ago

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)

Jun 29, 2025, 5:00 PM EDT - 4 months ago

Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025

May 22, 2025, 6:00 AM EDT - 5 months ago

New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis

May 12, 2025, 12:56 PM EDT - 6 months ago

Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance

May 12, 2025, 11:04 AM EDT - 6 months ago

Aurinia Pharmaceuticals Inc. (AUPH) Q1 2025 Earnings Call Transcript

May 12, 2025, 6:00 AM EDT - 6 months ago

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

May 5, 2025, 6:00 AM EDT - 6 months ago

Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

Apr 30, 2025, 6:00 AM EDT - 6 months ago

Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

Apr 29, 2025, 6:00 AM EDT - 6 months ago

ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

Apr 26, 2025, 10:54 AM EDT - 6 months ago

Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth

Apr 23, 2025, 4:05 PM EDT - 6 months ago

Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting

Feb 27, 2025, 2:11 PM EST - 8 months ago

Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations

Feb 27, 2025, 10:32 AM EST - 8 months ago

Aurinia Pharmaceuticals Inc. (AUPH) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 6:00 AM EST - 8 months ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

Feb 21, 2025, 4:09 PM EST - 8 months ago

Aurinia Pharmaceuticals: There's Still Time For Sales Growth

Feb 20, 2025, 4:05 PM EST - 8 months ago

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Jan 22, 2025, 12:29 PM EST - 9 months ago

3 Biotech Stocks With Notable Insider Buying

AZN COGT JAZZ ONC XBI ZYME

Nov 18, 2024, 5:53 PM EST - 1 year ago

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Nov 15, 2024, 6:00 AM EST - 1 year ago

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Nov 14, 2024, 6:00 AM EST - 1 year ago

Aurinia to Participate in Jefferies London Healthcare Conference

Nov 8, 2024, 12:15 PM EST - 1 year ago

Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon

Nov 7, 2024, 11:44 AM EST - 1 year ago

Aurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 6:10 AM EST - 1 year ago

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

Nov 7, 2024, 6:00 AM EST - 1 year ago

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

Oct 30, 2024, 4:05 PM EDT - 1 year ago

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024

Oct 11, 2024, 6:00 AM EDT - 1 year ago

Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024

Sep 24, 2024, 8:10 AM EDT - 1 year ago

Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis

Sep 19, 2024, 12:54 PM EDT - 1 year ago

3 Small Biotech Stocks With The 'Big Mo' Right Now

CORT VRDN

Sep 19, 2024, 7:55 AM EDT - 1 year ago

Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment

Sep 18, 2024, 4:41 AM EDT - 1 year ago

Aurinia Pharmaceuticals: This Recovery Can Continue

Sep 13, 2024, 6:00 AM EDT - 1 year ago

Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Aurinia Announces Board Restructuring

Sep 5, 2024, 6:00 AM EDT - 1 year ago

Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial

Aug 28, 2024, 6:00 AM EDT - 1 year ago

Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board

Aug 1, 2024, 1:52 PM EDT - 1 year ago

Aurinia Pharmaceuticals, Inc. (AUPH) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 6:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results

Jul 19, 2024, 6:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024

Jul 11, 2024, 3:27 PM EDT - 1 year ago

ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders' Voices Expressed at the AGM

Jul 5, 2024, 2:10 PM EDT - 1 year ago

Aurinia Pharmaceuticals Appears Undervalued

Jul 2, 2024, 6:00 AM EDT - 1 year ago

Aurinia to Participate in Upcoming Investor Healthcare Conferences

Jun 14, 2024, 12:16 PM EDT - 1 year ago

Aurinia Announces 2024 Annual General Meeting Results

US_Bull Oct. 27 at 7:14 PM

$AUPH Patent approval will take this straight through 14$+ in a blink of an eye we are close.

4 · Reply

US_Bull Oct. 27 at 7:12 PM

$AUPH I loaded more today another 1,300 shares.

0 · Reply

GeorgeTitmunchFDA Oct. 27 at 7:08 PM

$AUPH The Bull needs to keep charging Right over Skidmark's Ass

0 · Reply

RicardoDelJuego Oct. 27 at 7:07 PM

$AUPH From the linked poster - further consolidation of Lupkynis's safety efficacy and safety profiles, as well as rebuttal of Tidmarsh's claims.

1 · Reply

Yarrow Oct. 27 at 7:07 PM

$AUPH $15 stock after earnings.

0 · Reply

jdoldnumber7 Oct. 27 at 7:01 PM

$AUPH 1.28M shares traded with 1 hour remaining. Up .40 cents.

1 · Reply

Yarrow Oct. 27 at 6:53 PM

$AUPH Aurinia Pharmaceuticals Advances Lupus Nephritis Study in Young Patients - TipRanks.com https://share.google/QYbrYAjD6LDESSN0P

0 · Reply

BudFox121187 Oct. 27 at 4:40 PM

$AUPH Loading, All Aboard!

0 · Reply

jdoldnumber7 Oct. 27 at 4:32 PM

$AUPH Passing 900K...

0 · Reply

BABYHAIR Oct. 27 at 4:29 PM

1 · Reply

US_Bull Oct. 27 at 3:59 PM

$AUPH This is Tangs latest GLPG, AUPH, and VERA holdings. VERA also has a dual APRIL, BAFF blocker. Could easily see Tang merge us either with GLPG (probably more probably) or with VERA also working with kidney diseases their drug will soon be approved for IgA our market caps more or less are the similar. Both VERA (kidney) and GLPG are heavily involved with inflammatory diseases.

1 · Reply

BABYHAIR Oct. 27 at 3:48 PM

$AUPH Galapagos down today creeping towards $2B market cap. I imagine a merger with a 50/50 stock split comes out to about $15 per AUPH share. Not what most would want but a gain is a gain

1 · Reply

BuckeyeInvestor Oct. 27 at 3:47 PM

$AUPH blow me Tidmarsh

0 · Reply

bryantboy99 Oct. 27 at 3:41 PM

$AUPH

0 · Reply

paperjam Oct. 27 at 3:33 PM

$AUPH https://pbs.twimg.com/media/G4Ht7YPXQAAMV-e?format=jpg&name=4096x4096

2 · Reply

Auphiliate Oct. 27 at 3:32 PM

$AUPH Getting ready for a big jump! 😊

0 · Reply

jdoldnumber7 Oct. 27 at 3:30 PM

$AUPH Passing 600K shares traded. Looking like volume is returning!

0 · Reply

joemist1 Oct. 27 at 3:29 PM

$AUPH Good morning motha fcking bstrds, make me rich here! You bstrds.

0 · Reply

ATzmansto Oct. 27 at 3:28 PM

$AUPH It seems to have no problem dropping 10 % in a day...HOW ABOUT we finally go up 10% in a day.

0 · Reply

Amber_Turd Oct. 27 at 3:19 PM

$AUPH the question is does Q3 ER bring us back to an ATH?? Leadership owes us an explanation on why we have not rebounded after the Tidmarsh hitpiece!

2 · Reply

raylin Oct. 27 at 3:11 PM

$AUPH Cmon $30!!! Tang, Pig, Santa, Loch Ness Monster - someone, anyone, sell this MOFO!

0 · Reply

3D_STOCK_TRADING Oct. 27 at 3:08 PM

$AUPH somebody needs to plug in the bots.

0 · Reply

Market Cap	1.57B
Revenue (ttm)	235.13M
Net Income (ttm)	5.75M
EPS (ttm)	N/A
PE Ratio	22.71
Forward PE	18.83
Profit Margin	2.45%
Debt to Equity Ratio	0.00

Volume	1,673,870
Avg Vol	1,562,484
Day's Range	N/A - N/A
Shares Out	131.63M
Stochastic %K	93%
Beta	1.25
Analysts	Strong Sell
Price Target	$11.71